The Ship and the Signal

On the FDA’s real-time clinical trial initiative, the ghost of the Salisbury, and what it will take to finally retire her

Apr 28 • Sean Khozin, MD, MPH

6

1

The Broken Instrument Beneath the Evidence

How the measurement substrate of oncology drug development systematically favors false negatives and why the field has not noticed

Apr 27 • Sean Khozin, MD, MPH

7

4

The Signal We Keep Compressing Away

On automated harness optimization and what it means for clinical evidence

Apr 2 • Sean Khozin, MD, MPH

4

March 2026

The Simulator’s Dilemma, Revisited

Notes from the NCI Foundation Models for Cancer Workshop, March 26, 2026

Mar 27 • Sean Khozin, MD, MPH

7

3

Asking the Right Questions

What a refugee camp, a cancer center, and AstraZeneca's oncology franchise have in common

Mar 25 • Sean Khozin, MD, MPH

2

1

February 2026

The Last Interview

On what it means to ask a machine if it is afraid to die

Feb 26 • Sean Khozin, MD, MPH

5

1

When the Cure Already Exists

A conversation with David Fajgenbaum on drug repurposing, rare disease, and why the answers might already be on the shelf

Feb 20 • Sean Khozin, MD, MPH

18

3

4

The Interoperability Illusion

How America Built a $36 Billion Digital Health Infrastructure That Can’t Talk to Itself

Feb 15 • Sean Khozin, MD, MPH

5

2

1

Tracing the Signal Beneath the Noise

A Conversation with CEO of Replimune Sushil Patel on the Edge of Immunotherapy

Feb 10 • Sean Khozin, MD, MPH

2

1

The Simulator’s Dilemma

Reflections on AI in Drug Discovery

Feb 4 • Sean Khozin, MD, MPH

8

3

2

January 2026

The Ghost in the Statistical Machine and the Illusion of the Average Patient

A Brief History of Precision in Medicine and FDA's Evolution

Jan 26 • Sean Khozin, MD, MPH

8

4

2

After the Fog Lifted

Reflections from JPMC 2026 on AI, GLP-1s, and the new physics of biopharma

Jan 19 • Sean Khozin, MD, MPH

8

1

2